KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gains from Investment Securities (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Gains from Investment Securities for 17 consecutive years, with $73.2 million as the latest value for Q1 2026.

  • For Q1 2026, Gains from Investment Securities rose 2387.5% year-over-year to $73.2 million; the TTM value through Mar 2026 reached $608.5 million, down 40.69%, while the annual FY2025 figure was $532.1 million, 48.29% down from the prior year.
  • Gains from Investment Securities hit $73.2 million in Q1 2026 for Regeneron Pharmaceuticals, down from $519.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $772.8 million in Q3 2024 and bottomed at -$237.1 million in Q2 2022.
  • Average Gains from Investment Securities over 5 years is $74.5 million, with a median of $3.0 million recorded in 2024.
  • Year-over-year, Gains from Investment Securities crashed 3100.0% in 2025 and then surged 2387.5% in 2026.
  • Regeneron Pharmaceuticals' Gains from Investment Securities stood at -$169.0 million in 2022, then skyrocketed by 110.36% to $17.5 million in 2023, then surged by 1348.0% to $253.4 million in 2024, then surged by 104.89% to $519.2 million in 2025, then plummeted by 85.9% to $73.2 million in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $73.2 million, $519.2 million, and -$4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.